Geron to Present at the H.C. Wainwright Global Investment Conference
Geron Corporation (NASDAQ: GERN), a biopharmaceutical company focused on hematologic malignancies, announced that CEO John A. Scarlett will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
A webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.
About Geron
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005151/en/
Investor and Media Relations
investor@geron.com
media@geron.com
Source: